http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0617236-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2006-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df38540827b12a4d7b7f901c0483e67e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6df5c2b1103bafbab8b7cde8ee5e92 |
| publicationDate | 2011-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0617236-A2 |
| titleOfInvention | egfr-dependent modulation of chemokine expression and influence on tumor therapy and diagnosis and side effects |
| abstract | <B> MODULATION OF THE CHEMOCCIN EXPRESSION, EGFR DEPENDENT, AND INFLUENCE ON TUMOR THERAPY AND DIAGNOSIS OF THE SAME. <D> The present invention relates to the diagnosis and therapy of tumors using the epidermal growth factor (EGFR) by means of chemical inhibitors or monoclonal antibodies. The invention also relates to skin irritations, preferably skin rash, in conjunction with and associated with the treatment of tumor cells, which use the EGF receptor, with anticancer agents. The invention is also directed to methods for predicting the efficiency of a tumor therapy / tumor response in a patient, based on treatment with EGFR inhibitors, especially anti-EGFR antibodies. The invention further relates to a method for determining the optimal dose of an anticancer agent in the therapy of EGFR-related tumors. |
| priorityDate | 2005-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.